Cencora stock sets fiscal 2027 outlook after strong finish

Published on 11/05/2026 at 15:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora stock enters fiscal 2027 after a stronger fourth quarter and a new operating structure. Management lifted the quarterly dividend by 10%.

Cencora enters fiscal 2027

Fourth-quarter revenue increased 5.5% to USD 88.4 billion.
Adjusted diluted EPS rose 21.4% to USD 4.66, while adjusted operating income increased 22.1%.
Management expects fiscal 2027 adjusted EPS of USD 19.40 to USD 19.75 and revenue growth of 3% to 5%.
A new reporting structure separates pharmaceutical distribution from specialty pharmaceutical and provider services.

Cencora Inc., US03073E1055, Illustration mit AI erstellt.

Cencora reported fiscal 2026 fourth-quarter and full-year results on Wednesday, November 4, with revenue growth, stronger adjusted profitability and a new operating model shaping the outlook for the pharmaceutical solutions group. The company expects fiscal 2027 adjusted diluted EPS of USD 19.40 to USD 19.75.

According to the Cencora investor release, fourth-quarter revenue rose 5.5% year over year to USD 88.4 billion. GAAP diluted EPS was USD 2.71, compared with a loss of USD 1.75 in the prior-year quarter, while adjusted diluted EPS increased 21.4% to USD 4.66.

What changed after the latest report

Adjusted operating income increased 22.1% to USD 1.2 billion. Adjusted gross profit advanced 23.0% to USD 3.6 billion, while the adjusted gross margin expanded to 4.04%. Cencora said the February 2026 acquisition of OneOncology supported profitability, although higher GLP-1 sales carried lower gross margins.

For the full fiscal year ended September 30, revenue increased 5.0% to USD 337.4 billion and adjusted diluted EPS climbed 12.3% to USD 17.97. The company also reorganized its reporting structure ahead of fiscal 2027, with Pharmaceutical Distribution and Services and Specialty Pharmaceutical and Provider Services becoming the main reportable segments.

Outlook and capital priorities

Cencora expects fiscal 2027 revenue to grow 3% to 5% and adjusted operating income to increase 4% to 6%. Pharmaceutical Distribution and Services is expected to deliver revenue growth of 4% to 6%, while Specialty Pharmaceutical and Provider Services is expected to grow revenue 9% to 14% and operating income 18% to 21%.

The outlook assumes the sale of the Profarma equity interest closes in the first fiscal quarter and that the MWI Animal Health merger with Covetrus closes by March 31, 2027. Cencora expects adjusted free cash flow of USD 3.5 billion and capital expenditures of USD 1.0 billion. The quarterly dividend was raised 10% to USD 0.66 per share, payable November 30 to shareholders of record November 13.

Cencora stock traded at EUR 322.80 on Lang & Schwarz at 15:37 CET on Thursday, November 5, 2026. Compared with the EUR 293.65 quote in the October 27 report, the difference was 9.93%.